Trevi Shares Rise Following GSK's Discontinuation of Chronic Cough Therapy
GSK announced plans to discontinue its chronic cough therapy after a late-stage trial failure. Trevi Therapeutics, which is developing an alternative treatment for the same condition, saw its stock rise and reach an all-time high.
Topics: clinical trial failure drug development rival company stock movement